SHL Group is exhibiting at the 2019 BIO International Convention in Philadelphia, Pennsylvania, USA from June 3-6.
SHL will showcase its vast portfolio of drug delivery systems designed to accommodate a wide range of drugs and biologics in a variety of volumes and viscosities. SHL representatives will also introduce its vertically integrated solutions for device development programs, including precision design and engineering capabilities, turnkey solutions for final assembly, labeling, and packaging, as well analytical testing solutions for both sub-assemblies and fully assembled combination products.
This will mark SHL's third year participating in the annual event. Business Development Director, Taras Seniuch, commented: "SHL understands the intricacies of the self-injection process and the complexities of combination product development timelines. SHL combines years of knowledge and experience with a strong set of in-house capabilities to help our partners ensure the successful commercialization of their combination product in a timely manner. We're excited to meet with our partners from across the biotech industry to learn how we can further support their drug development programs."
Bio International attracts more than 16,000 industry leaders from over 7,000 companies worldwide and it is the largest global networking and exhibiting event for the biotechnology industry.
To learn more, visit SHL at Booth 2455 at the Pennsylvania Convention Center.
SHL Group is a world-leading solution provider in the design, development and manufacturing of advanced drug delivery devices such as auto injectors, pen injectors and advanced inhaler systems. We also offer core competencies and services in the fields of medtech and patient care solutions. With locations in Taiwan, Switzerland, Sweden, China and the US, our experienced engineers and designers develop product enhancements as well as breakthrough drug delivery and patient care solutions for pharma and biotech clients globally. Significant investment in R&D has enhanced our broad pipeline of next-generation drug delivery systems that support ongoing innovations in drug development and digital healthcare. This includes advanced reusable and disposable injectors that can accommodate high volume and high viscosities and can be enhanced through digital implementations.
With over 4,000 employees worldwide, SHL Group consists of several distinct group companies:
SHL Medical designs, develops and manufactures advanced drug delivery devices, as well as provides final assembly, labeling and packaging services for leading pharmaceutical and biotech companies across the globe.
SHL Healthcare develops and manufactures equipment solutions for home, hospital and long term care use.
SHL Technologies provides contract manufacturing and engineering services for the production of complex medtech and industrial products.
For additional information, visit www.shl.group.